N4 Pharma Plc (AIM: N4P), provide details of its work plan following the encouraging data from its oncology research as announced on 13 December 2021. The company sounded very positive with the update released this week.
Share talk spoke with Nigel Theobald, covering the latest announcement and asking him about the market response to news being released by the company, current share price and how often do they have to update the markets?
Have you fully funded all current work streams in Q1/2 in 2022, yes we have more than sufficient funds to carry out the work planned, just a few of the topics raised in the podcast.
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
https://www.share-talk.com/nigel-theobald-chief-executive-officer-n4-pharma-plc-lonn4p-interview/
Listen On
Also Listen
-
Zak Mir Talks to Howard White, Non-Executive Chairman of Hydrogen Utopia Intl
Zak Mir talks to Howard White, Chairman of Hydrogen Utopia, a company specialisi -
Greg Martr, the Executive Chairman of Capital Metals Talks To Zak Mir
Zak Mir talks to Greg Martyr, Executive Chairman, Capital Metals as the mineral -
Interview: Roadside Real Estate – Insights from CEO Charles Dixon
In a recent engaging conversation with Zak Mir, CEO of Roadside Real Estate, Cha -
Fulcrum Metals – Revolutionising Precious Metals Recovery from Tailings in Canada
In today’s feature, we delve deep into the exciting developments at Fulcrum Meta